<p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）的股票在 BTIG Research 发布的研究报告中重新获得了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价为 9.00 美元。BTIG Research 的目标价暗示该股票的潜在上涨空间为 52.39%。</p>
<p>获取 <strong>Organogenesis</strong> 的提醒：</p>
<p>其他一些股票研究分析师也对该股票发表了看法。Weiss Ratings 在周一的报告中重申了对 Organogenesis 股票的 “卖出（d+）” 评级。华尔街 Zen 在 11 月 8 日的研究报告中将 Organogenesis 的评级从 “持有” 上调至 “强力买入”。两位研究分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Organogenesis 的共识评级为 “持有”，平均目标价为 8.00 美元。</p>
<p><strong>查看我们关于 Organogenesis 的最新研究报告</strong></p>
<h2>Organogenesis 股价上涨 2.7%</h2>
<p>周五，ORGO 的开盘价为 5.91 美元。该公司的市值为 7.4953 亿美元，市盈率为-49.22，贝塔值为 1.47。Organogenesis 的 12 个月最低价为 2.61 美元，最高价为 7.08 美元。该股票的 50 日移动平均价为 5.03 美元，200 日移动平均价为 4.59 美元。该公司的流动比率为 3.32，速动比率为 2.88，债务与股本比率为 0.01。</p>
<p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益为 0.18 美元，超出分析师共识预期的 0.07 美元，超出幅度为 0.11 美元。该公司季度收入为 1.5086 亿美元，而分析师预期为 1.3410 亿美元。Organogenesis 的净利润率为-1.30%，股本回报率为 4.01%。整体来看，研究分析师预测 Organogenesis 在本年度将发布-0.07 美元的每股收益。</p>
<h2>内部活动</h2>
<p>在相关消息中，董事 Glenn H. Nussdorf 于 12 月 16 日（星期二）出售了 200,000 股 Organogenesis 股票。该股票的平均售价为 5.14 美元，总交易额为 1,028,000.00 美元。出售完成后，该董事持有公司 2,565,591 股股票，价值 13,187,137.74 美元。此次交易使其持股减少了 7.23%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此链接获取。过去三个月，内部人士共出售了价值 2,620,120 美元的 500,000 股公司股票。公司内部人士持有公司股票的 33.00%。</p>
<h2>机构投资者对 Organogenesis 的看法</h2>
<p>几家对冲基金最近增加或减少了对 ORGO 的持股。First Light Asset Management LLC 在第三季度将其在 Organogenesis 的持股增加了 10.6%。First Light Asset Management LLC 目前持有 7,497,911 股公司股票，价值 31,641,000 美元，在此期间又增持了 720,748 股。Assenagon Asset Management S.A.在第三季度将其在 Organogenesis 的持股增加了 69.9%。Assenagon Asset Management S.A.目前持有 4,854,942 股公司股票，价值 20,488,000 美元，在上个季度又购买了 1,997,038 股。Vanguard Group Inc.在第一季度将其在 Organogenesis 的持股增加了 23.4%。Vanguard Group Inc.目前持有 4,431,414 股公司股票，价值 19,144,000 美元，在此期间又增持了 841,618 股。Acadian Asset Management LLC 在第二季度将其在 Organogenesis 的持股增加了 3.9%。Acadian Asset Management LLC 目前持有 2,424,363 股公司股票，价值 8,862,000 美元，在此期间又增持了 91,118 股。最后，Driehaus Capital Management LLC 在第一季度购买了 Organogenesis 的新股份，价值 7,756,000 美元。49.57% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Organogenesis 公司简介</h2>
<p>（获取免费报告）</p>
<p>Organogenesis Inc 是一家专注于开发、制造和商业化创伤护理、外科修复和运动医学治疗解决方案的再生医学公司。该公司的产品组合满足各种急性和慢性组织修复需求，利用生物工程皮肤替代物、人类胎盘衍生产品和其他旨在促进愈合和减少疤痕的同种异体移植物。Organogenesis 将其疗法销售给医院、门诊诊所、创伤护理中心和其他医疗服务提供者。</p>
<p>主要产品包括 Apligraf，一种用于治疗糖尿病足溃疡和静脉性腿部溃疡的活性皮肤替代物；Dermagraft，一种冷冻保存的人类成纤维细胞衍生真皮替代物；Grafix，一种用于复杂和慢性创伤的胎盘膜同种异体移植物；以及 TheraSkin，一种用于外科和重建手术的冷冻保存人类皮肤同种异体移植物。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票比 Organogenesis 更好</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>在美国鬼城发现价值 100 万亿美元的 “人工智能金属”</li>
<li>华盛顿为战争做准备</li>
<li>在 1 月 1 日之前将 1000 美元投入这只股票 [不是 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Organogenesis 吗？</h2>
<p>在你考虑 Organogenesis 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Organogenesis 并不在名单上。</p>
<p>虽然 Organogenesis 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ORGO

<p>BTIG Research 重申了对 Organogenesis（NASDAQ:ORGO）的 “买入” 评级，目标价格为 9.00 美元，暗示潜在上涨空间为 52.39%。其他分析师的评级则不一，普遍为 “持有”，平均目标价格为 8.00 美元。Organogenesis 报告的季度收益超出预期，每股收益为 0.18 美元，收入为 1.5086 亿美元。内部人士活动包括大量股票出售，机构投资者已调整在该公司的持股比例</p>

<p>Organogenesis (NASDAQ:ORGO - Get Free Report)'s stock had its &#34;buy&#34; rating reissued by analysts at BTIG Research in a research note issued on Friday,Benzinga reports. They presently have a $9.00 price objective on the stock. BTIG Research's price objective would suggest a potential upside of 52.39% from the stock's current price.</p>
<div class="lb-trans"><p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）的股票在 BTIG Research 发布的研究报告中重新获得了 “买入” 评级，Benzinga 报道。他们目前对该股票的目标价为 9.00 美元。BTIG Research 的目标价暗示该股票的潜在上涨空间为 52.39%。</p>
</div><p>Get <strong>Organogenesis</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Organogenesis</strong> 的提醒：</p>
</div><p>A number of other equities research analysts have also weighed in on the stock. Weiss Ratings restated a &#34;sell (d+)&#34; rating on shares of Organogenesis in a report on Monday. Wall Street Zen upgraded Organogenesis from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Saturday, November 8th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Organogenesis has a consensus rating of &#34;Hold&#34; and an average target price of $8.00.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也对该股票发表了看法。Weiss Ratings 在周一的报告中重申了对 Organogenesis 股票的 “卖出（d+）” 评级。华尔街 Zen 在 11 月 8 日的研究报告中将 Organogenesis 的评级从 “持有” 上调至 “强力买入”。两位研究分析师给予该股票 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Organogenesis 的共识评级为 “持有”，平均目标价为 8.00 美元。</p>
</div><p><strong>View Our Latest Research Report on Organogenesis</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Organogenesis 的最新研究报告</strong></p>
</div><h2>Organogenesis Trading Up 2.7%</h2>
<div class="lb-trans"><h2>Organogenesis 股价上涨 2.7%</h2>
</div><p>ORGO opened at $5.91 on Friday. The firm has a market cap of $749.53 million, a P/E ratio of -49.22 and a beta of 1.47. Organogenesis has a 12 month low of $2.61 and a 12 month high of $7.08. The stock has a 50-day moving average of $5.03 and a 200 day moving average of $4.59. The company has a current ratio of 3.32, a quick ratio of 2.88 and a debt-to-equity ratio of 0.01.</p>
<div class="lb-trans"><p>周五，ORGO 的开盘价为 5.91 美元。该公司的市值为 7.4953 亿美元，市盈率为-49.22，贝塔值为 1.47。Organogenesis 的 12 个月最低价为 2.61 美元，最高价为 7.08 美元。该股票的 50 日移动平均价为 5.03 美元，200 日移动平均价为 4.59 美元。该公司的流动比率为 3.32，速动比率为 2.88，债务与股本比率为 0.01。</p>
</div><p>Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.18 earnings per share for the quarter, topping analysts' consensus estimates of $0.07 by $0.11. The company had revenue of $150.86 million for the quarter, compared to analyst estimates of $134.10 million. Organogenesis had a negative net margin of 1.30% and a positive return on equity of 4.01%. As a group, research analysts forecast that Organogenesis will post -0.07 EPS for the current year.</p>
<div class="lb-trans"><p>Organogenesis（纳斯达克代码：ORGO - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益为 0.18 美元，超出分析师共识预期的 0.07 美元，超出幅度为 0.11 美元。该公司季度收入为 1.5086 亿美元，而分析师预期为 1.3410 亿美元。Organogenesis 的净利润率为-1.30%，股本回报率为 4.01%。整体来看，研究分析师预测 Organogenesis 在本年度将发布-0.07 美元的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, Director Glenn H. Nussdorf sold 200,000 shares of Organogenesis stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the completion of the sale, the director owned 2,565,591 shares of the company's stock, valued at $13,187,137.74. The trade was a 7.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 500,000 shares of company stock valued at $2,620,120 over the last three months. Company insiders own 33.00% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Glenn H. Nussdorf 于 12 月 16 日（星期二）出售了 200,000 股 Organogenesis 股票。该股票的平均售价为 5.14 美元，总交易额为 1,028,000.00 美元。出售完成后，该董事持有公司 2,565,591 股股票，价值 13,187,137.74 美元。此次交易使其持股减少了 7.23%。该交易已在向 SEC 提交的文件中披露，相关文件可通过此链接获取。过去三个月，内部人士共出售了价值 2,620,120 美元的 500,000 股公司股票。公司内部人士持有公司股票的 33.00%。</p>
</div><h2>Institutional Investors Weigh In On Organogenesis</h2>
<div class="lb-trans"><h2>机构投资者对 Organogenesis 的看法</h2>
</div><p>Several hedge funds have recently added to or reduced their stakes in ORGO. First Light Asset Management LLC lifted its holdings in Organogenesis by 10.6% in the third quarter. First Light Asset Management LLC now owns 7,497,911 shares of the company's stock valued at $31,641,000 after acquiring an additional 720,748 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Organogenesis by 69.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 4,854,942 shares of the company's stock valued at $20,488,000 after purchasing an additional 1,997,038 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Organogenesis by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 4,431,414 shares of the company's stock valued at $19,144,000 after purchasing an additional 841,618 shares during the period. Acadian Asset Management LLC lifted its stake in shares of Organogenesis by 3.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,424,363 shares of the company's stock valued at $8,862,000 after purchasing an additional 91,118 shares during the period. Finally, Driehaus Capital Management LLC purchased a new stake in Organogenesis during the first quarter worth $7,756,000. 49.57% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家对冲基金最近增加或减少了对 ORGO 的持股。First Light Asset Management LLC 在第三季度将其在 Organogenesis 的持股增加了 10.6%。First Light Asset Management LLC 目前持有 7,497,911 股公司股票，价值 31,641,000 美元，在此期间又增持了 720,748 股。Assenagon Asset Management S.A.在第三季度将其在 Organogenesis 的持股增加了 69.9%。Assenagon Asset Management S.A.目前持有 4,854,942 股公司股票，价值 20,488,000 美元，在上个季度又购买了 1,997,038 股。Vanguard Group Inc.在第一季度将其在 Organogenesis 的持股增加了 23.4%。Vanguard Group Inc.目前持有 4,431,414 股公司股票，价值 19,144,000 美元，在此期间又增持了 841,618 股。Acadian Asset Management LLC 在第二季度将其在 Organogenesis 的持股增加了 3.9%。Acadian Asset Management LLC 目前持有 2,424,363 股公司股票，价值 8,862,000 美元，在此期间又增持了 91,118 股。最后，Driehaus Capital Management LLC 在第一季度购买了 Organogenesis 的新股份，价值 7,756,000 美元。49.57% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Organogenesis Company Profile</h2>
<div class="lb-trans"><h2>Organogenesis 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company's product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.</p>
<div class="lb-trans"><p>Organogenesis Inc 是一家专注于开发、制造和商业化创伤护理、外科修复和运动医学治疗解决方案的再生医学公司。该公司的产品组合满足各种急性和慢性组织修复需求，利用生物工程皮肤替代物、人类胎盘衍生产品和其他旨在促进愈合和减少疤痕的同种异体移植物。Organogenesis 将其疗法销售给医院、门诊诊所、创伤护理中心和其他医疗服务提供者。</p>
</div><p>Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.</p>
<div class="lb-trans"><p>主要产品包括 Apligraf，一种用于治疗糖尿病足溃疡和静脉性腿部溃疡的活性皮肤替代物；Dermagraft，一种冷冻保存的人类成纤维细胞衍生真皮替代物；Grafix，一种用于复杂和慢性创伤的胎盘膜同种异体移植物；以及 TheraSkin，一种用于外科和重建手术的冷冻保存人类皮肤同种异体移植物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Organogenesis</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>$100 Trillion “AI Metal” Found in American Ghost Town</li>
<li>Washington prepares for war</li>
<li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li>
<li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 Organogenesis 更好</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>在美国鬼城发现价值 100 万亿美元的 “人工智能金属”</li>
<li>华盛顿为战争做准备</li>
<li>在 1 月 1 日之前将 1000 美元投入这只股票 [不是 NVDA]</li>
<li>将你的 “死钱” 转变为每月 306 美元以上（从这个月开始）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Organogenesis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Organogenesis 吗？</h2>
</div><p>Before you consider Organogenesis, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Organogenesis 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organogenesis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Organogenesis 并不在名单上。</p>
</div><p>While Organogenesis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Organogenesis 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Organogenesis（ORGO）的 “买入” 评级在 BTIG 研究中再次被确认